BI Asset Management Fondsmaeglerselskab A S Sells 27,047 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

BI Asset Management Fondsmaeglerselskab A S lessened its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 42.1% during the 1st quarter, HoldingsChannel reports. The fund owned 37,249 shares of the company’s stock after selling 27,047 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Teva Pharmaceutical Industries were worth $1,122,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of TEVA. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth $25,000. Allworth Financial LP lifted its position in Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. Grove Bank & Trust lifted its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 51.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Teva Pharmaceutical Industries by 567.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after purchasing an additional 1,134 shares during the period. Institutional investors own 54.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Barclays boosted their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. UBS Group increased their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Piper Sandler restated an “overweight” rating and set a $42.00 target price (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Transactions at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. This represents a 34.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Eliyahu Sharon Kalif sold 106,563 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $34.10, for a total value of $3,633,798.30. Following the transaction, the executive vice president owned 65,621 shares of the company’s stock, valued at $2,237,676.10. This represents a 61.89% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 465,931 shares of company stock valued at $16,332,989. 0.54% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $34.20 on Thursday. The firm has a market cap of $39.33 billion, a price-to-earnings ratio of 25.72, a P/E/G ratio of 3.74 and a beta of 0.84. The firm has a fifty day moving average price of $33.66 and a 200 day moving average price of $32.35. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The company had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.14 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.